Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
Identifying high-impact solutions to address racial and ethnic health disparities in lupus: A consensus-based approach
This study used a consensus-based approach to identify high-impact solutions for reducing racial and ethnic health disparities in lupus. Through a literature...